Long before “forever chemicals” entered the public vocabulary, before the EPA set a federal limit, and before Congress allocated billions for PFAS cleanup, there was a cattle farmer in Parkersburg, West Virginia whose herd was dying — and a corporate defense lawyer who decided to figure out why.
The story of DuPont’s C8 contamination of the Mid-Ohio Valley is the foundational case of the American PFAS crisis. It produced the largest community biomonitoring study in US history, a landmark epidemiological panel that established the first definitive links between PFOA exposure and human disease, nearly a billion dollars in personal-injury settlements, and eventually the multi-billion-dollar national reckoning that is still playing out today. Understanding what happened in Parkersburg is essential context for understanding the 2024 EPA PFAS rule and the PFAS settlement deadlines facing utilities across the country.
A Cattle Farmer in Parkersburg
In 1998, Wilbur Tennant, a cattle farmer in Parkersburg, West Virginia, had lost 153 animals. The cattle that drank from Dry Run Creek — a stream that ran along the edge of a landfill DuPont was operating nearby — grew tumors, went blind, and died with blackened organs. Tennant had documented the deaths on videotape, hours of footage showing dead and deformed animals, and he had tried for years to get someone to explain what was happening.
He found Rob Bilott through a family connection. Bilott was a partner at Taft Stettinius & Hollister in Cincinnati, a firm that represented chemical companies. He was, in the conventional sense, exactly the wrong kind of lawyer for Tennant to call. But Bilott agreed to look at the videotapes. What he saw led him to request documents from DuPont under the legal discovery process. Those documents changed his career and, eventually, federal regulatory policy.
DuPont had been using a chemical called PFOA — perfluorooctanoic acid, known internally as C8 — as a processing aid in Teflon production at its Washington Works plant near Parkersburg since the 1950s. The chemical was sourced from 3M. It had been discharged into the Ohio River, buried in the Dry Run Landfill, and emitted from the plant’s stacks. It had seeped into groundwater and entered the drinking water of communities on both sides of the Ohio River.
The documents Bilott obtained revealed something more troubling: DuPont had conducted internal studies on C8 toxicity in workers and animals for decades. The company had found elevated rates of disease among plant workers. It had performed animal studies showing C8 caused tumors. It had detected C8 in the blood of workers’ family members — including newborns. None of this had been disclosed to regulators, to the communities whose water systems drew from sources downstream of Washington Works, or to the public.
How C8 Got Into Six Water Systems
The Washington Works plant sits on the Ohio River between Parkersburg, West Virginia and Belpre, Ohio. For decades, its PFOA discharges — through wastewater, atmospheric deposition, and landfill leachate — migrated through groundwater and surface water into the source water for municipal and rural drinking water systems on both sides of the state line.
By the time Bilott’s investigation had proceeded far enough to file a class-action lawsuit in 2001, six public water districts serving roughly 70,000 residents were confirmed to have C8-contaminated drinking water.
| Water District | State | Notes |
|---|---|---|
| Lubeck Public Service District | WV | Closest downstream system; highest early concentrations |
| Mason County Public Service District | WV | Served rural communities along the river |
| Little Hocking Water Association | OH | Across the Ohio River from Washington Works |
| Tuppers Plains-Chester Water District | OH | Further downstream along the Ohio |
| Belpre, City of | OH | Adjacent to Washington Works on the Ohio side |
| Pomeroy, Ohio | OH | Downstream river intake |
The class action — filed on behalf of all residents served by these six systems — set in motion a legal process that would run for more than a decade, produce a scientific panel that became a model for community health research, and ultimately force a national reckoning with how PFOA and its chemical relatives had been manufactured, used, and discarded across the United States.
What DuPont Knew (and When)
The internal documents that emerged through discovery in Bilott’s lawsuit told a detailed story of corporate knowledge and deliberate non-disclosure.
DuPont’s own medical division had begun studying PFOA’s effects on workers in the 1960s. By the 1970s, internal studies had documented that C8 passed through the placenta — a finding that prompted DuPont to quietly move pregnant women out of exposed jobs, without informing them why. In the 1980s, DuPont found elevated rates of testicular cancer among Washington Works employees. Animal studies conducted by or for the company showed that PFOA caused liver, testicular, and pancreatic tumors in rats. A 1984 internal document acknowledged that C8 was “very toxic” in animal studies.
The company had also commissioned studies of C8 in the blood of people living near Washington Works. The results showed contamination well beyond the plant fence line. DuPont monitored the contamination. It did not report findings to the EPA, to West Virginia or Ohio environmental agencies, or to the communities whose tap water it was entering.
In 2001, Bilott did something unusual: he wrote directly to the EPA, enclosing the internal DuPont documents. That letter triggered an EPA investigation that confirmed the extent of contamination and led, eventually, to a $16.5 million EPA civil penalty against DuPont in 2004 — at the time, the largest civil administrative penalty in the agency’s history — for violating the Toxic Substances Control Act by failing to report evidence of PFOA’s risks.
The penalty was notable not because it was large — it was a rounding error for a company of DuPont’s scale — but because it validated, on the public record, that DuPont had possessed evidence of toxicity and had withheld it from regulators for years.
The Lawsuit and the C8 Science Panel
The 2001 class action moved slowly. In 2004, a settlement was reached on the question of medical monitoring — not yet on personal-injury damages. The settlement created something unprecedented: an independent scientific panel, funded by DuPont, tasked with determining whether PFOA caused specific diseases in the contaminated communities.
The panel was formally called the C8 Science Panel, and the conditions of the settlement were unusual. DuPont agreed that if the panel found “probable links” between PFOA exposure and any disease, class members diagnosed with those diseases could bring individual personal-injury lawsuits — and DuPont agreed not to contest that PFOA caused those specific conditions. In effect, DuPont was funding the science that would determine its own liability for individual claims.
The science panel’s work began with what became known as the C8 Health Project: a community blood-testing program that ran from 2005 to 2006 and enrolled nearly 70,000 residents — essentially the entire population of the six affected water districts. Participants provided blood samples, completed detailed health and exposure questionnaires, and consented to follow-up research. It became the largest community PFAS biomonitoring study in United States history.
From that foundation, the panel — composed of independent epidemiologists and biostatisticians — spent eight years analyzing the data, reviewing the published literature, and conducting its own studies. In 2012 and 2013, it released its findings.
The Six Diseases the Panel Linked to PFOA
The C8 Science Panel concluded that there was a “probable link” between PFOA exposure and six specific diseases. The probable link standard was defined in the settlement as a finding that PFOA “more likely than not” caused the disease in the exposed population — a civil liability standard, not a regulatory threshold.
| Disease | Notes from Panel Findings |
|---|---|
| Kidney cancer | Statistically significant elevated rates in exposed population |
| Testicular cancer | Elevated rates consistent with DuPont’s own internal worker studies |
| Thyroid disease | Dose-response relationship observed; disruption of thyroid hormone pathways |
| Ulcerative colitis | Elevated rates of this inflammatory bowel disease |
| Pregnancy-induced hypertension (preeclampsia) | Associated with PFOA exposure during pregnancy |
| High cholesterol (hypercholesterolemia) | Among the most consistent and dose-dependent findings |
These findings were scientifically significant well beyond the Parkersburg case. They provided the strongest human epidemiological evidence then available for PFOA’s carcinogenicity — evidence later incorporated into the International Agency for Research on Cancer’s 2023 classification of PFOA as a Group 1 human carcinogen (sufficient evidence of carcinogenicity in humans). They also established a template that regulators have used when evaluating health evidence for the broader PFAS class. For a full discussion of PFAS health effects, see our PFAS contaminant profile.
From Individual Claims to a National Reckoning
With the science panel’s probable-link findings in hand, thousands of individual personal-injury claims proceeded under the terms of the class settlement. A group of bellwether trials in federal court in Ohio tested DuPont’s liability for specific plaintiffs with kidney cancer, testicular cancer, and ulcerative colitis.
DuPont lost all three bellwether cases — Bartlett, Freeman, and Vigneron — with juries awarding damages in each. The losses were not individually catastrophic for the company, but they signaled that the litigation would be expensive and that DuPont’s exposure across thousands of remaining claims was enormous.
In 2017, DuPont and Chemours — the chemicals spinoff DuPont had created in 2015 to hold, among other liabilities, its PFAS-related obligations — announced a settlement of approximately 3,550 personal-injury cases for $670.7 million. The settlement resolved claims from residents of the six water districts who had been diagnosed with one of the six probable-link diseases. It did not resolve claims from plaintiffs outside that geographic area, and it did not end the litigation history of C8 — it accelerated it, because the story was now national.
By the time the 2019 film “Dark Waters” — directed by Todd Haynes, with Mark Ruffalo playing Bilott — dramatized the case for a mass audience, the implications of what had happened in Parkersburg had already expanded far beyond West Virginia and Ohio. Bilott’s 2019 memoir “Exposure” provided the detailed account behind the film.
The 2023 Multi-System Settlements
The same pattern that Bilott had used against DuPont — obtain internal documents, build the scientific record, litigate bellwether cases — had been replicated across dozens of jurisdictions by hundreds of attorneys representing water utilities, municipalities, and states. By 2022 and 2023, the litigation had consolidated into a massive multidistrict proceeding in federal court in South Carolina before Judge Richard Gergel.
Two landmark settlements emerged in 2023:
3M’s settlement — announced in June 2023 — committed the company to pay between $10.3 billion and $12.5 billion (depending on the number of eligible water systems that join) to resolve claims from US public water systems for PFAS contamination caused by AFFF (aqueous film-forming foam) and other 3M products. The payments are structured over time from 2024 through 2036. 3M’s primary PFAS liability relates to PFOS — a distinct compound from PFOA — but the settlement covers the full family of PFAS contamination traceable to 3M products.
DuPont, Chemours, and Corteva’s settlement — announced in June 2023 separately — committed those three entities (Corteva was spun off from DuPont in 2019) to pay $1.185 billion to resolve public water system claims related to PFOA and related DuPont-lineage PFAS. Chemours and Corteva each contribute specific shares; DuPont contributes the remainder.
| Settlement | Parties | Amount | Coverage |
|---|---|---|---|
| 3M water-system settlement | 3M | $10.3B–$12.5B | PFOS and other 3M PFAS in public water systems |
| DuPont/Chemours/Corteva settlement | DuPont, Chemours, Corteva | $1.185B | PFOA and DuPont-lineage PFAS in public water systems |
| 2017 personal-injury settlement | DuPont and Chemours | $670.7M | ~3,550 individual claimants in six WV/OH water districts |
These settlements do not release all claims — state attorneys general, additional private plaintiffs, and ongoing environmental cleanup obligations are separate matters — but they represent the largest PFAS liability resolutions in US history and will fund testing and treatment at water utilities across the country for years to come. The deadlines for utilities to file claims in these proceedings are consequential; systems that miss the filing windows may forfeit access to settlement funds.
Where the Cleanup Stands
In the Mid-Ohio Valley itself, the cleanup is real but incomplete. Lubeck Public Service District installed a granular activated carbon (GAC) treatment system in 2007 — making it one of the first public water utilities in the United States to install full-system PFAS treatment. The installation came out of an interim settlement that also provided bottled water and filtration to affected residents while the larger litigation proceeded.
GAC treatment at the 4 parts-per-trillion standard required by the 2024 EPA PFAS rule is significantly more demanding than what utilities were targeting in 2007. Utilities that installed early treatment systems are now evaluating whether their existing infrastructure achieves the new MCL. Those that don’t meet 4 ppt will need to upgrade or supplement their treatment — additional GAC beds, ion exchange, or reverse osmosis.
The source contamination at Washington Works has not been fully remediated. DuPont’s successor entities have conducted groundwater treatment at the site under state and federal oversight, but PFOA persists in the soils, sediments, and shallow aquifers around the plant. The half-life of PFOA in the environment is measured not in years but in decades to centuries under most conditions. Complete cleanup of a site with decades of PFOA discharge is not a near-term prospect with current technology.
Private wells in the surrounding area remain a concern. Residents on private well water were outside the class of the original settlement (which covered public water system customers) and have had fewer resources for testing or treatment. For households relying on private groundwater near any industrial PFAS source, the private wells PFAS guide outlines testing options and treatment approaches.
Why Parkersburg Still Matters
The story that started with a cattle farmer’s dying herd in 1998 now shapes how the United States regulates an entire class of industrial chemicals. The direct line from Tennant’s farm to the 2024 EPA PFAS rule runs through the C8 Science Panel’s findings, through the personal-injury verdicts, and through the national litigation that forced DuPont, 3M, and their successors to begin paying for the contamination their products caused.
Several consequences of the Parkersburg case continue to reverberate:
PFOA as a regulatory model. The C8 Science Panel’s methodology — large-scale community blood testing, independent epidemiology, transparent publication of findings — established a template for community health investigations that has been applied in other PFAS-affected communities. The panel’s probable-link diseases are now codified in EPA guidance and state health advisories.
Corporate liability for knowing concealment. DuPont and 3M’s internal documentation showed that both companies possessed evidence of PFAS toxicity decades before that evidence became public. Courts have accepted that concealment as relevant to punitive damages, and those findings have influenced how regulators approach TSCA disclosure requirements and how legislators think about chemical safety law reform.
The settlement funding gap. The 2023 settlements — $10.3 to $12.5 billion from 3M, $1.185 billion from DuPont’s successors — sound enormous. EPA estimated the annualized cost of compliance with the PFOA/PFOS MCLs at $772 million to $1.2 billion per year. Spread across the thousands of utilities that will need treatment upgrades and the decades those systems will operate, the settlement funds cover a fraction of the total remediation cost. The remainder falls to ratepayers, federal grants under the Bipartisan Infrastructure Law, and state revolving fund allocations.
The precedent for successor liability. DuPont’s corporate restructuring — spinning off PFAS-related operations into Chemours in 2015 and agricultural operations into Corteva in 2019 — was challenged in litigation as an attempt to insulate the core DuPont company from liability. Courts have found that the successor entities cannot fully escape the obligations that came with the assets they received. That precedent has implications for other industries where corporate restructuring has been used to separate profitable businesses from environmental liabilities.
The replacement-chemistry problem. When DuPont phased PFOA out of its US operations under the 2006 EPA Stewardship Program, it transitioned to a short-chain ether-PFAS called HFPO-DA, marketed as GenX. That replacement was manufactured at the Chemours plant in Fayetteville, North Carolina — and contaminated drinking water for roughly 250,000 people downstream on the Cape Fear River. The Cape Fear / GenX case is the direct sequel to Parkersburg: a “safer” alternative introduced without independent toxicology, then discovered in finished drinking water years later. The pattern raises a structural question about how new industrial chemicals enter commerce ahead of the regulatory science.
What This Means For You
If your water comes from a public system, the consequences of Parkersburg are tangible. The 2024 EPA PFAS rule — with its 4 ppt MCL for PFOA — exists in large part because the C8 Science Panel provided the human health evidence that made a strict limit scientifically and legally defensible. Your utility is likely in the process of testing, evaluating treatment options, or accessing settlement funds to pay for them. The settlement deadline calendar for utilities is a live issue for your water provider right now.
If your water comes from a private well near any industrial facility, military base, or landfill, the Parkersburg case is a reminder that PFOA contamination can extend miles from its source and persist for decades. Testing is the only way to know. See our private wells PFAS guide for how to order a certified lab test and what results mean.
If you want to remove PFOA and related PFAS from your tap water at home regardless of what your utility reports, reverse osmosis systems achieve greater than 90% removal of most PFAS compounds, including PFOA. Under-sink RO is the most cost-effective residential option. GAC-based filters certified under NSF P473 reduce long-chain PFAS but are less reliable for the full class. Boiling water does not remove PFAS; it makes concentrations worse by evaporating water and leaving dissolved chemicals behind.
Search your city on WaterVerge to see current PFAS detection results for your utility, any violations on record, and how concentrations compare to the new federal MCLs. For the full picture on PFAS as a chemical class — what they are, where they come from, and which treatment technologies actually work — see our companion piece: PFAS in drinking water.
Related Coverage
- PFAS in Drinking Water — what the full class of forever chemicals is, how they enter water, and how to remove them
- The 2024 EPA PFAS Rule — the first federal MCLs and what utilities must do to comply
- PFAS Settlement Deadlines for Utilities — 3M and DuPont/Chemours filing windows and what utilities need to know
- Cape Fear & GenX: PFOA’s Successor Chemical — how the chemical that replaced C8 contaminated water for 250,000 North Carolinians
- PFAS: A Primer — accessible overview of the science and policy
- Private Wells and PFAS — testing and treatment for households not on public water
- Best Reverse Osmosis Systems — tested home filtration for PFAS removal